Selling the front door

SELLING THE front door while keeping the factory is a strange way to build a franchise. Yet that is what Joerns Healthcare has spent three years doing. This week the American maker of hospital beds, patient lifts and pressure-relieving mattresses said it had sold its Netherlands-based sales-and-service business to Avance Care Group, a Dutch consolidator, handing over exclusive distribution rights in the Netherlands and other parts of the Benelux region — Belgium, the Netherlands and Luxembourg — while retaining its designs, factories and brands. Terms were undisclosed. The deal is the third such sale in three years, and the pattern says more about its industry than any single transaction does.

Joerns is an old name in a hard corner of medicine. Founded in 1889, and owned by private equity since 2010, when Quad-C Management and its management bought it from Vestar Capital Partners, it sells to the post-acute world — the nursing homes, hospices and home-care agencies that hoist frail elderly residents from bed to chair. Its brands carry the musty authority of incumbency: the Hoyer lift, marketed as the gold standard of patient hoists, and the EasyCare and UltraCare beds. Authority is not the same as profit. In 2019 the company filed for prepackaged Chapter 11 — American bankruptcy protection whose terms are settled in advance — proposing to swap $320m of its $400m of debt for equity. It emerged with debt cut to $80m from $400m and its lenders ruined: junior bondholders recovered two to four cents on the dollar, after a year in which the group lost $72.6m on its way into court, having been short of liquidity since 2016.

The trouble was structural, not managerial. Post-acute providers — nursing homes above all — were collapsing under falling occupancy and changing reimbursements, and the bankruptcies of its own customers left equipment makers holding fleets nobody was renting. Joerns' model was to rent beds and lifts to cash-constrained homes for a monthly fee, a business built on the regularity of public reimbursement. When the payment system changed, so did the economics. In 2023 the firm announced it was leaving institutional renting altogether, citing a post-pandemic shift in customer preference away from renting toward owning and reimbursements moving from fee-for-service — the traditional payment per treatment — toward a patient-directed model. It has been divesting ever since: its south-eastern American rental network went to MasVida Health in 2024, its British Oxford-brand safe patient handling business to Prism Healthcare later that year, and now the Dutch operation.

The retreat itself deserves credit. What Joerns has kept is, on its face, the better half: the product designs, the intellectual property, the factories and an internet-connected platform (Connexio) meant to make its beds and lifts manage themselves. Shedding an asset-heavy rental fleet and thin-margin foreign distribution to concentrate capital on North American sales is exactly what a sensible owner would do. Doug Ferguson, chief executive since 2025, insists the aim is to "accelerate innovation" and deepen partnerships with beleaguered providers. As restructuring chores go, this one is unfolding with unusual tidiness.

The trouble is what each tidy deal gives away. Three times Joerns has sold distribution rights and kept a factory, and the market's revealed preference is that distribution is the valuable part. Distribution is where the switching costs live: a nursing home that has standardised on a lift, trained its staff and signed a service contract does not change supplier lightly. That is a moat. Manufacturing, by contrast, is a commodity whose unit costs depend on volume from a shrinking customer footprint. The buyers see the same thing. Avance — formerly the JOYinCARE group, a consolidator of Dutch care-equipment suppliers that took Knop Investments as its majority shareholder in 2025 — and Prism and MasVida are all accumulating instalments of installed base, not factories.

Then comes the second-order effect. Once Avance owns the Joerns relationship with Dutch care homes, it controls the front door; nothing stops it meeting the next tender with a cheaper rival hoist, leaving Joerns' retained brand to compete only from a distance. Intellectual property without a route to market is a filing, not a moat.

None of this can be checked from outside. Joerns is privately held; its deals are struck in private; the only public financial record of the modern company is its 2019 bankruptcy. That drought is itself part of the story: the discipline comes from a sponsor's internal rate of return, not from the scrutiny of public markets. Even so, the verdict is harsh. Sixteen years of private-equity ownership, punctuated by a bankruptcy that wiped out the bondholders, is not value creation; it is salvage — competent, orderly, upbeat-sounding salvage.

The wider lesson concerns payment, not pluck. America's retreat from fee-for-service was defensible in intent, but reforms that reroute money have consequences for the machinery that serves the reformed system's own clients. The collapse of equipment rental stranded balance-sheets, pushed the company through court and is now feeding an international consolidation of distributors. A reform that changes where the money flows should pause to consider what it breaks along the way.

For Joerns, the remaining question is whether North America can fill the hole left by everywhere else. The retreat is rational; the bet is not. A company that keeps selling its front door is assuming its factory matters more than its doorstep — an assumption its own buyers are betting against.